Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and immunogenicity of a
13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given
concomitantly with routine pediatric vaccines in France.